Cite
NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer
MLA
Samuel A. Jacobs, et al. “NSABP FB-7: A Phase II Randomized Neoadjuvant Trial with Paclitaxel + Trastuzumab and/or Neratinib Followed by Chemotherapy and Postoperative Trastuzumab in HER2+ Breast Cancer.” Breast Cancer Research, vol. 21, no. 1, Dec. 2019, pp. 1–11. EBSCOhost, https://doi.org/10.1186/s13058-019-1196-y.
APA
Samuel A. Jacobs, André Robidoux, Jame Abraham, José Manuel Pérez-Garcia, Nicla La Verde, James M. Orcutt, Marina E. Cazzaniga, Fanny Piette, Silvia Antolín, Elena Aguirre, Javier Cortes, Antonio Llombart-Cussac, Serena Di Cosimo, Rim S. Kim, Huichen Feng, Corey Lipchik, Peter C. Lucas, Ashok Srinivasan, Ying Wang, … Katherine L. Pogue-Geile. (2019). NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer. Breast Cancer Research, 21(1), 1–11. https://doi.org/10.1186/s13058-019-1196-y
Chicago
Samuel A. Jacobs, André Robidoux, Jame Abraham, José Manuel Pérez-Garcia, Nicla La Verde, James M. Orcutt, Marina E. Cazzaniga, et al. 2019. “NSABP FB-7: A Phase II Randomized Neoadjuvant Trial with Paclitaxel + Trastuzumab and/or Neratinib Followed by Chemotherapy and Postoperative Trastuzumab in HER2+ Breast Cancer.” Breast Cancer Research 21 (1): 1–11. doi:10.1186/s13058-019-1196-y.